RxDoctor Payments Data

Daniel Megna, MD

Gastroenterology · Staten Island, NYNPI 1235119660

Payments from drug & device makers

$13,116in general payments, 2019–2025

Across 760 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$849
  • Ardelyx, Inc.$643
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$12,92099%
  • Education$150%
  • Other$1821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,116 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$576,165
Medicare patients
834
Services billed
2,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Famotidine2,075$42,029
LinzessLinaclotide42$39,246
CreonLipase/Protease/Amylase23$30,163
Mesalamine45$23,566
Lansoprazole433$12,253
Dexlansoprazole DrDexlansoprazole37$11,708
Pantoprazole Sodium787$9,990
ViberziEluxadoline12$9,176
Omeprazole444$6,961
InvokanaCanagliflozin11$6,192
Mesalamine ErMesalamine17$5,199
Dicyclomine Hcl177$3,777
CholestyramineCholestyramine (With Sugar)15$3,746
Esomeprazole Magnesium89$2,683
Balsalazide Disodium22$2,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$2,865$78,58477 claims
Johnson & JohnsonInvokana$1,054$6,19211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →